News

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of ...
INDIANAPOLIS, May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab ...
Eli Lilly courts physicians with blockbuster-topping Taltz data In the June data presentation, 36% of patients treated with Taltz hit both markers at 24 weeks, topping Humira, which saw only 28% ...
Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out ...
INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz ® (ixekizumab) injection 80 mg/mL ...
The minute-long commercial, featuring lots of bare shoulders, midriffs and swimsuits, promotes a new drug by Eli Lilly and Co. called Taltz that treats red, scaly patches of skin caused by ...
Two decades ago, Eli Lilly and Co. boasted just one ... While many new products are fueling Lilly’s turnaround, Taltz, launched in 2016, is an especially key driver. The company spent hundreds ...
Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment ...
That showed Taltz was able to work well and achieve the primary goal in both studies. The first late-stage study, known as COAST-V, evaluated patients who didn't take any antirheumatic drug ...
Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for ...